| variable | Total | male | female | unknown | |
|---|---|---|---|---|---|
| 1 | Year | ||||
| 2 | 2018 | 126(15.50) | 59(46.83) | 66(52.38) | 1(0.79) |
| 3 | 2019 | 283(34.81) | 122(43.11) | 151(53.36) | 10(3.53) |
| 4 | 2020 | 94(11.56) | 37(39.36) | 51(54.26) | 6(6.38) |
| 5 | 2021 | 68( 8.36) | 33(48.53) | 31(45.59) | 4(5.88) |
| 6 | 2022 | 51( 6.27) | 23(45.1) | 26(50.98) | 2(3.92) |
| 7 | 2023 | 75( 9.23) | 31(41.33) | 35(46.67) | 9(12) |
| 8 | 2024 | 79( 9.72) | 46(58.23) | 30(37.97) | 3(3.8) |
| 9 | 2025 | 37( 4.55) | 15(40.54) | 21(56.76) | 1(2.7) |
| 10 | age_yr | 56.00(48.00,65.00) | 56.00(45.00,64.50) | 57.00(49.00,65.00) | 65.00(40.00,65.00) |
| 11 | age_yrQ | ||||
| 12 | 18-40 | 87(10.70) | 47(54.02) | 38(43.68) | 2(2.3) |
| 13 | 40-60 | 130(15.99) | 60(46.15) | 70(53.85) | 0(0) |
| 14 | 60-80 | 164(20.17) | 76(46.34) | 85(51.83) | 3(1.83) |
| 15 | >=80 | 0( 0.00) | 0(NaN) | 0(NaN) | 0(NaN) |
| 16 | unknow | 432(53.14) | 183(42.36) | 218(50.46) | 31(7.18) |
| 17 | wt | 80.50(67.00,95.81) | 87.05(77.00,101.50) | 70.30(60.00,91.80) | 98.00(98.00,98.00) |
| 18 | wtQ | ||||
| 19 | ＜50 | 4( 0.49) | 0(0) | 4(100) | 0(0) |
| 20 | 50-100 | 134(16.48) | 63(47.01) | 70(52.24) | 1(0.75) |
| 21 | >=100 | 34( 4.18) | 23(67.65) | 11(32.35) | 0(0) |
| 22 | unknow | 641(78.84) | 280(43.68) | 326(50.86) | 35(5.46) |
| 23 | Reporter | ||||
| 24 | Consumer | 491(60.39) | 221(45.01) | 251(51.12) | 19(3.87) |
| 25 | Pharmacist | 158(19.43) | 59(37.34) | 88(55.7) | 11(6.96) |
| 26 | Physician | 139(17.10) | 76(54.68) | 60(43.17) | 3(2.16) |
| 27 | Other health-professional | 16( 1.97) | 8(50) | 6(37.5) | 2(12.5) |
| 28 | unknown | 9( 1.11) | 2(22.22) | 6(66.67) | 1(11.11) |
| 29 | Reported countries | ||||
| 30 | United States | 641(78.84) | 279(43.53) | 328(51.17) | 34(5.3) |
| 31 | China | 105(12.92) | 47(44.76) | 58(55.24) | |
| 32 | Germany | 24( 2.95) | 14(58.33) | 9(37.5) | 1(4.17) |
| 33 | other | 19( 2.34) | 11(57.89) | 8(42.11) | |
| 34 | Italy | 7( 0.86) | 4(57.14) | 3(42.86) | |
| 35 | Australia | 6( 0.74) | 5(83.33) | 1(16.67) | |
| 36 | Portugal | 6( 0.74) | 2(33.33) | 3(50) | 1(16.67) |
| 37 | Poland | 5( 0.62) | 4(80) | 1(20) | |
| 38 | route | ||||
| 39 | oral | 766(94.22) | 348(45.43) | 391(51.04) | 27(3.52) |
| 40 | other | 47( 5.78) | 18(38.3) | 20(42.55) | 9(19.15) |
| 41 | Outcomes | ||||
| 42 | other serious | 206(48.36) | 108(52.43) | 93(45.15) | 5(2.43) |
| 43 | hospitalization | 169(39.67) | 90(53.25) | 79(46.75) | |
| 44 | life threatening | 31( 7.28) | 22(70.97) | 8(25.81) | 1(3.23) |
| 45 | disability | 13( 3.05) | 11(84.62) | 2(15.38) | |
| 46 | death | 6( 1.41) | 5(83.33) | 1(16.67) | |
| 47 | required intervention to Prevent Permanent Impairment/Damage | 1( 0.23) | 1(100) | ||
| 48 | tto | 13.00(3.00,91.00) | 21.00(3.00,114.50) | 10.00(3.00,56.00) | 0.00(0.00,0.00) |
| 49 | ttoQ | ||||
| 50 | 小于7 | 61(15.25) | 26(42.62) | 34(55.74) | 1(1.64) |
| 51 | 7-30 | 48(12.00) | 19(39.58) | 29(60.42) | 0(0) |
| 52 | 30-60 | 13( 3.25) | 8(61.54) | 5(38.46) | 0(0) |
| 53 | 60-90 | 7( 1.75) | 5(71.43) | 2(28.57) | 0(0) |
| 54 | 90-364 | 34( 8.50) | 21(61.76) | 13(38.24) | 0(0) |
| 55 | >=364 | 12( 3.00) | 4(33.33) | 8(66.67) | 0(0) |
| 56 | unknow | 225(56.25) | 97(43.11) | 126(56) | 2(0.89) |
| 57 | Indications | ||||
| 58 | blood_glucose_abnormal | 54( 6.64) | 25(46.3) | 29(53.7) | |
| 59 | others | 2( 0.25) | 1(50) | 1(50) | |
| 60 | type_2_diabetes_mellitus | 503(61.87) | 231(45.92) | 265(52.68) | 7(1.39) |
| 61 | unknown | 254(31.24) | 109(42.91) | 116(45.67) | 29(11.42) |